logo-loader
viewActinium Pharmaceuticals Inc

Actinium Pharmaceuticals' Phase 3 blood cancer fighting drug results expected this fall

Actinium Pharmaceuticals Inc (OTCMKTS: ATNRW) CEO Sandesh Seth tells Proactive's Christine Corrado the biotech's flagship cancer fighting drug, Iomab-B, is currently in Phase 3, with results expected this fall, and an FDA filing expected in early 2020.

Seth says the drug targets elderly, acute myeloid leukemia patients, what he says is the deadliest form of blood cancer known to man.

Seth says the elderly can't tolerate chemotherapy drugs, and often die from the treatment. In contrast, Seth says Actinium's drug replaces chemo, with a bone marrow translate and cure rate of about 20%.

Quick facts: Actinium Pharmaceuticals Inc

Price: 0.2123 USD

NYSE:ATNM
Market: NYSE
Market Cap: $64.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ioneer Ltd's Bernard Rowe hails new boric acid distribution and sales agreements

ioneer Ltd's (ASX:INR) Bernard Rowe speaks to Proactive's Andrew Scott after securing two distribution and sales agreements for the supply of boric acid from its Rhyolite Ridge Lithium-Boron Project in Nevada, USA. The three-year boric acid distribution and sales agreements were signed with...

18 hours, 57 minutes ago

2 min read